Investment Research Radio

Purecore Metals: A New Critical Minerals Story | Peter Berdusco, Founder & CEO

In this five-minute episode of Investment Research Radio, I sit down with Peter Berdusco, Founder and CEO of Purecore Metals, a newly listed Canadian mining junior trading on the Canadian Securities Exchange (CSE: PURE), the OTCQB (OTCQB: PPURF) and the Frankfurt Stock Exchange (FSE: J8Y).

Peter shares the story behind Purecore's inception, its focus on critical minerals including uranium and copper, and its exploration properties in Saskatchewan and British Columbia. We discuss the company's early development as a public company and its opportunity to participate in growing demand for nuclear energy, electrification and critical mineral supply.

This is the first in a planned series of short, five minute conversations with founders and executives building emerging companies.

Learn more: https://purecoremetals.com/

In this episode of Investment Research Radio, Ray Crowley speaks with Maunark Patel, Co-Founder and CEO of Skuvent, about the operational challenges medical device manufacturers face managing inventory, implants, and surgical equipment across warehouses, sales representatives, hospitals, and operating rooms.

The conversation explores how Skuvent is addressing gaps in medical device field operations, including inventory tracking, consignment management, surgical case coordination, product transfers, expiration monitoring, audits, and integration with existing ERP and CRM systems.

Maunark shares the story behind Skuvent, the problems the company aims to solve for medical device manufacturers, and the broader opportunity to improve visibility, accountability, and efficiency across complex medical device supply chains. We also discuss the competitive landscape, commercialization strategy, and Maunark's vision for the company's future.

Join us for a conversation about the business of medical technology, the operational challenges facing device manufacturers, and the opportunity to modernize how medical devices move from the warehouse to the point of care.

https://www.skuvent.com

What if glucose monitoring could be done without needles, using sweat sensing technology instead?

In this episode of Investment Research Radio, I speak with Lu Yin, CEO and Co-Founder of Persperion, a company developing finger touch based sweat sensing technology with an initial focus on non-invasive glucose monitoring.

We discuss the science behind Persperion's approach, the challenges of developing accurate non-invasive biosensors, and the potential to make health monitoring more accessible and convenient. We also explore the broader opportunity for sweat-based diagnostics and how advances in sensing technology could open the door to monitoring additional biomarkers in the future.

As Persperion advances its technology toward clinical validation and commercialization, we discuss the development milestones, regulatory considerations, and market opportunities involved in bringing a new medical technology to patients.

Tune in to hear Lu's perspective on building a deep technology company and the future of non invasive diagnostics.

https://persperion.com/

In this episode of Investment Research Radio, Ray Crowley speaks with John Sanwo, Founder and CEO of WearableDose, about the company's development of precision radiation detection technology.

WearableDose is developing wearable radiation sensing technology designed to support radiation monitoring and safety across applications such as healthcare, oncology, defense, aerospace and other environments where radiation exposure is a concern.

Ray and John discuss the technology behind WearableDose, the challenges of developing wearable radiation detection systems, potential applications across different industries, and the company's journey toward commercialization.

The conversation explores the growing role of advanced sensing technologies in improving radiation awareness, monitoring and safety for people working in environments where exposure matters.

Tune in to learn more about WearableDose, its technology and John's vision for the future of wearable radiation detection.

https://wearabledose.com/

NeuroDyne with CEO Dr. Mark Myers | Investment Research Radio

In this episode of Investment Research Radio, Ray Crowley speaks with Dr. Mark Myers, CEO and CTO of NeuroDyne, about the company's work in wearable electroencephalography (EEG) technology and its development of a wearable EEG cap designed to measure brain activity.

Dr. Myers discusses the technology behind NeuroDyne's approach, its potential applications in neurological monitoring and healthcare, and the company's progress toward FDA Class II clearance.

We explore the challenges of bringing innovative neurotechnology to market, the potential for future product iterations and applications, and the opportunities for wearable brain monitoring as neuroscience and medical technology continue to advance.

Tune in to learn more about NeuroDyne's technology, its development journey, and Dr. Myers' vision for the future of wearable EEG.

https://www.neurodyneinc.com/

Derek Dashti, Founder of D&P Bioinnovations | Rebuilding Damaged Tissue From Within

In this episode of Investment Research Radio, I speak with Derek Dashti, founder of D&P Bioinnovations, about a potentially transformative approach to regenerative medicine.

D&P Bioinnovations is developing an implantable, bioresorbable medical technology designed to help the body regenerate damaged tissue rather than simply repair or replace it. The company's approach combines engineered biomaterials with biological signals derived from stem cells to create an environment that can encourage the body's own cells to rebuild damaged tissue.

The company's initial focus is one of the most difficult areas of tissue repair: the esophagus. Severe damage caused by conditions such as cancer can require highly invasive reconstructive procedures, sometimes involving the use of another part of the patient's body to replace the damaged esophagus. D&P's approach is aimed at something fundamentally different: using a temporary implant to support the body's own regenerative processes and potentially restore the tissue from within.

What makes the science so interesting is the possibility that the technology could extend beyond a single organ or disease. If the underlying regenerative approach can be successfully translated into human therapies, it could have applications across a range of damaged tissues.

Derek and I discuss the science behind the technology, what led him to pursue regenerative medicine, the challenges of moving from laboratory research toward clinical applications, and where he believes this technology could ultimately lead.

A fascinating conversation about regenerative medicine, biotechnology, entrepreneurship, and the possibility of changing how damaged human tissue is treated.

dpbioinnovations.com

In this episode of Investment Research Radio, I sit down with Claire Dixon, CEO and Co-Founder of Neuraura, to explore the technology behind the company's next generation approach to neural sensing and stimulation.

Neuraura is developing advanced microelectrode technology designed to both record neural activity and stimulate neural tissue, opening potential applications that go beyond conventional sensing technologies.

We discuss the origins of Neuraura, its connection to the University of Calgary and the research that led to the company's technology, as well as the journey from academic research to commercial development.

Claire explains the technology behind Neuraura's microelectrodes, including the importance of the interface between the technology and the body, and how sensing and stimulation could potentially be combined to create new approaches to monitoring and treatment.

We also discuss LoOoP by Neuraura, the company's work in women's health and PCOS, the broader applications of its underlying technology, clinical development, regulatory considerations and the company's vision for the future.

The conversation also covers Neuraura's financing journey, including early investment, non-dilutive funding and the capital required to advance its technology toward clinical validation and commercialization.

• Claire Dixon's background and the origins of Neuraura • The University of Calgary research behind the technology • Neuraura's microelectrode technology • Neural sensing and neural stimulation • Why the technology goes beyond conventional sensors • The potential for closed loop sensing and stimulation • Microneedle and minimally invasive approaches • LoOoP by Neuraura and women's health • PCOS/PMOS and the company's current focus • Potential applications beyond the company's current products • Clinical development and regulatory pathways • Neuraura's major milestones • The company's financing history and use of capital • Future financing and development milestones • Partnerships and commercialization • Claire's vision for Neuraura

neuraura.com

In this episode of Investment Research Radio, we explore Regulify, an AI powered platform designed to help MedTech companies navigate the complex regulatory, quality, risk and product development processes required to bring medical devices to market.

Regulify goes beyond simply adding AI to an existing software system. The platform is designed as an intelligence layer connecting regulatory, quality, product development, risk, clinical evidence and other critical functions across the MedTech product lifecycle.

We discuss why traditional regulatory and quality workflows can be fragmented, how Regulify works alongside existing eQMS platforms, and how its AI driven approach can help companies manage changes, identify regulatory requirements, streamline documentation and potentially reduce the time and resources required to bring products to market.

We also explore Regulify's competitive landscape, the technology behind the platform, its potential to change how MedTech companies manage their regulatory and quality infrastructure, and what could make the platform difficult to replicate.

Whether you are a MedTech founder, medical device executive, regulatory professional, investor or strategic partner, this conversation provides an inside look at the growing role of AI in medical device development and regulatory compliance.

In this episode we discuss: • The origins of Regulify • The regulatory and quality challenges facing MedTech companies • What Regulify is and how the platform works • Regulify's AI powered intelligence layer • Connecting regulatory, quality, risk, clinical and product development workflows • How Regulify works with existing eQMS platforms • FDA regulatory processes and time to market • The competitive landscape • Regulify's technology and potential defensibility • The future of AI in MedTech regulation and product development

Investment Research Radio features conversations with founders, executives and innovators building the companies and technologies shaping the future of healthcare, technology and industry.

regulify.ai

Jake Edick, Entirety Biomedical: Reinventing Bioabsorbable Implants with Curasorb

In this episode of Investment Research Radio, I sit down with Jake Edick, founder of Entirety Biomedical, to explore the future of medical implants and the company's Curasorb platform, a next generation approach to bioabsorbable orthopedic hardware.

Traditional permanent implants, including titanium hardware, can provide the structural support surgeons need, but they can also remain in the body long after their job is done. Entirety Biomedical is developing a different approach: implants designed to provide temporary mechanical support and then gradually resorb as the body heals.

Jake takes us inside the technology behind Curasorb, including Entirety's work with magnesium and its decision to pursue a non coated magnesium implant. We discuss what differentiates the platform from other bioabsorbable implant technologies and how the company believes its approach could create value for both surgeons and patients.

We also discuss the company's regulatory and clinical development pathway, the applications Entirety is pursuing, its commercialization strategy, and the opportunity Jake sees for bioabsorbable implants across orthopedic surgery.

Jake recently led Entirety Biomedical through its seed financing, so we also talk about what the company is using the capital to accomplish, the milestones ahead, and what it will take to move from promising technology toward clinical and commercial adoption.

In this episode we discuss: • Jake's background in medical devices and biomaterials • The limitations of permanent titanium hardware • The problem Entirety Biomedical was created to solve • The Curasorb bioabsorbable implant platform • Magnesium as an implant material • Why Entirety is developing a non coated magnesium implant • How Curasorb differs from other bioabsorbable technologies • Potential benefits for patients and surgeons • FDA and clinical development milestones • Target applications and commercialization strategy • Entirety Biomedical's recent seed financing • The company's growth plans and upcoming milestones • Jake's five year vision for Entirety Biomedical • The broader opportunity in bioabsorbable medical devices

https://www.entiretybio.com

Ray Crowley Interviews Craig Nicol, CEO of Graphene Manufacturing Group

In this episode of Investment Research Radio, Ray sits down with Craig Nicol, Founder, CEO and Managing Director of Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTC: GMGMF) (Frankfurt: 0GF), to discuss the evolution of GMG from a graphene producer into a vertically integrated advanced materials and energy technology company.

The conversation explores five interconnected assets and potential revenue streams built around GMG's proprietary graphene platform:

1. Graphene Raw Material Craig explains GMG's proprietary graphene manufacturing technology and the recent commissioning of its Gen 2.0 production plant, designed to produce up to 10 tonnes of graphene annually once fully optimized. The in-house production capability gives GMG control over material quality, supply and cost while providing the foundation for its downstream products.

2. THERMAL-XR® The discussion then moves to GMG's commercial energy savings business. THERMAL-XR® is a graphene enhanced coating designed to improve heat transfer and protect HVAC and industrial heat exchange equipment. With US EPA approval, North American distribution through Nu-Calgon and record June 2026 sales orders exceeding A$400,000, this represents GMG's most immediate commercial revenue opportunity.

3. G® LUBRICANT Ray and Craig discuss GMG's graphene lubricant additive, designed to reduce friction, fuel consumption and emissions in engines and other industrial applications. GMG has reported independently verified fuel efficiency improvements of up to 8.4% in diesel engine testing. The opportunity is to build recurring product revenue through distributors and industrial customers.

4. SUPA G® Battery Material The fourth layer of the business is GMG's proprietary graphene slurry for lithium ion batteries. Rather than having to manufacture an entire battery, SUPA G® potentially allows GMG to sell a specialized material into existing battery manufacturing supply chains. This creates another pathway to monetize the graphene platform while battery manufacturers evaluate performance improvements.

5. G CELLS™ Graphene Aluminium Ion Battery Finally, the conversation looks at GMG's highest value and longest term opportunity: its graphene aluminium ion battery technology. Developed with the University of Queensland and supported by Australian government funding, the technology is being advanced toward larger cells, manufacturing processes and eventual commercialization. This could ultimately move GMG from selling materials and additives into supplying an entire next generation energy storage technology.

Ray and Craig discuss how these five assets create a layered commercialization strategy: produce the raw material, sell graphene enabled products, supply graphene into other manufacturers' batteries, and ultimately develop GMG's own battery technology.

The conversation also looks ahead to GMG's expansion into North America and Europe, additional industrial applications, data centre cooling, strategic partnerships and the potential for modular graphene production facilities. Craig explains how the company's near term focus is converting commercial product adoption into revenue while continuing to invest in the much larger battery opportunity.

The central investment story is therefore not simply graphene production alone. It is GMG's attempt to build an integrated materials platform where one proprietary graphene manufacturing capability supports multiple products, and multiple revenue streams.